Home / Market News / $SUPN

$SUPN news and market catalysts

The 12 most recent market catalysts affecting $SUPN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

12 catalysts 6 high impact 10 bullish 0 bearish Pharmaceuticals
Nov 6, 2026 Corporate Catalyst Neutral Impact 60
Supernus, Inc. Confirms Special Cash Dividend Payment to Former Indivior Stockholders
Supernus, Inc. has completed a key financial obligation stemming from its merger with Indivior Pharmaceuticals, Inc. by distributing a $1 billion special cash dividend to former In…
Nov 4, 2026 Corporate Catalyst Bullish Impact 65
Piper Sandler Resumes Supernus Pharmaceuticals at Overweight
Piper Sandler has reinstated coverage on Supernus Pharmaceuticals with an 'Overweight' rating and a $47 price target. This positive analyst action is driven by the strategic merger…
Nov 4, 2026 Corporate Catalyst Bullish Impact 65
Piper Sandler Resumes Coverage of Supernus Pharmaceuticals
Piper Sandler resuming coverage of Supernus Pharmaceuticals with an overweight rating and a $47 price target is a significant positive development for the company. The analyst's ra…
Nov 4, 2026 Corporate Catalyst Bullish Impact 75
Piper Sandler Resumes Coverage of Supernus Pharmaceuticals Following Indivior Merger Announcement
Piper Sandler has resumed coverage of Supernus Pharmaceuticals, upgrading its outlook to 'overweight' with a $47 price target. This positive re-evaluation is directly linked to the…
Nov 2, 2026 Corporate Catalyst Bullish Impact 95
Supernus Pharmaceuticals Completes Merger With Indivior Pharmaceuticals
Supernus Pharmaceuticals and Indivior Pharmaceuticals have finalized their merger, forming a new, larger entity focused on the central nervous system (CNS) biopharmaceutical market…
Nov 2, 2026 Corporate Catalyst Bullish Impact 85
Supernus Secures $650 Million Senior Secured Term Loan
Supernus Pharmaceuticals has successfully secured a $650 million senior secured term loan. This financing is crucial as it directly funds the merger with Indivior Pharmaceuticals, …
Oct 29, 2026 Market Technicals Neutral Impact 55
S&P Dow Jones Indices Announces Index Reconstitution Change
S&P Dow Jones Indices announced a minor, one-day delay in the S&P SmallCap 600 index reconstitution, moving the effective date from November 2 to November 3, 2026. This change is a…
Aug 3, 2026 Corporate Catalyst Bullish Impact 95
Supernus Pharma shares are trading higher after the company reported better-than-expected Q2 financial results. The company also announced a merger with Indivior Pharma to create diversified, CNS biopharmaceutical company.
This headline represents a major corporate catalyst for both Supernus Pharma and Indivior Pharma. The combination of better-than-expected earnings for Supernus and a strategic merg…
Aug 3, 2026 Corporate Catalyst Bullish Impact 95
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in a tax-free all-stock deal, creating a significant player in the CNS biopharmaceutical space. This merger is hig…
Aug 3, 2026 Corporate Catalyst Bullish Impact 92
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate
Supernus Pharmaceuticals (SUPN) announced Q2 adjusted EPS of $0.53, handily beating the consensus estimate of $0.42 by over 26%. This is a significant positive surprise, demonstrat…
Aug 3, 2026 Market Technicals Bullish Impact 55
12 Health Care Stocks Moving In Monday's Pre-Market Session
The filing details pre-market trading activity for 12 healthcare stocks, highlighting both significant gainers and losers. The most notable event is Supernus Pharmaceuticals' (SUPN…
Aug 3, 2026 Corporate Catalyst Bullish Impact 95
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock transaction, forming a new CNS biopharmaceutical company. This deal is significant as it creates a…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.